On Wednesday, RXi Pharmaceuticals Corp (NASDAQ:RXII)’s shares declined -2.76% to $0.700.
RXi Pharmaceuticals Corp (RXII) stated its financial results for the fourth quarter and year ended December 31, 2014, and offered a business update.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Sprouts Farmers Market Inc (NASDAQ:SFM)’s shares dropped -2.76% to $33.24.
Sprouts Farmers Market Inc (SFM) declared it will issue financial results for the first quarter ended March 29, 2015 after the market closes on Thursday, May 7, 2015. Following the release, Sprouts administration will conduct a conference call at 2 p.m. PDT (5 p.m. EDT) to talk about the results for the quarter.
Sprouts Farmers Market, Inc. operates as a specialty retailer of fresh, natural, and organic food in the United States. The company’s stores offer fresh produce, bulk foods, vitamins and supplements, grocery products, meat and seafood products, deli and bakery products, dairy and dairy alternatives, frozen foods, beer and wine, natural health and body care products, and natural household products.
At the end of Wednesday’s trade, Mylan NV (NASDAQ:MYL)‘s shares dipped -2.70% to $66.77.
Mylan NV (MYL) declared that its auxiliaries Mylan Inc. and Mylan Pharmaceuticals Inc. have reached a settlement and license contract with Pfizer Inc., Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation regarding Mylan’s Abbreviated New Drug Application filed with the U.S. Food and Drug Administration for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra®, which is indicated to treat erectile dysfunction.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Under the terms of the contract, Mylan will be able to launch its ANDA products following a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license contract are confidential, and the contract itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Smart & Final Stores Inc (NYSE:SFS), ended its Wednesday’s trading session with -2.53% loss, and closed at $18.50.
Smart & Final Stores Inc (SFS) declared that it will report its financial results for the first quarter ended March 22, 2015, on Tuesday, April 28, 2015, after the close of market. David Hirz, President and Chief Executive Officer, and Richard Phegley, Senior Vice President and Chief Financial Officer, will host a conference call to talk about the results at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time.
Smart & Final Stores, Inc. operates as a food retailer in the United States. The company operates through two segments, Smart & Final and Cash & Carry. It operates non-membership warehouse-style grocery stores under the Smart & Final banner in California, Arizona, and Nevada, in addition to under the Cash & Carry banner in Washington, Oregon, California, Idaho, and Nevada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
